Condition
Renal Clear Cell Carcinoma
Total Trials
5
Recruiting
2
Active
3
Completed
1
Success Rate
100.0%+13% vs avg
Key Insights
Highlights
Success Rate
100% trial completion (above average)
Clinical Risk Assessment
Based on trial outcomes
Moderate Risk
Score: 50/100
Termination Rate
0.0%
0 terminated out of 5 trials
Success Rate
100.0%
+13.5% vs benchmark
Late-Stage Pipeline
0%
0 trials in Phase 3/4
Results Transparency
0%
0 of 1 completed with results
Key Signals
100% success
Data Visualizations
Phase Distribution
3Total
Not Applicable (1)
P 2 (2)
Trial Status
Recruiting2
Completed1
Active Not Recruiting1
Withdrawn1
Trial Success Rate
100.0%
Benchmark: 86.5%
Based on 1 completed trials
Clinical Trials (5)
Showing 5 of 5 trials
NCT07332923Active Not RecruitingPrimary
Predicting HIF-2α Levels in Clear Cell Kidney Cancer Using Machine Learning
NCT06852638Not ApplicableRecruiting
CD70-targeted immunoPET Imaging of Malignant Cancers
NCT02819596Phase 2CompletedPrimary
MEDI4736 Combinations in Metastatic Renal Cell Carcinoma
NCT06211790Phase 2Recruiting
Proteomic Guided First-line Precision Treatment of Renal Clear Cell Carcinoma
NCT04680416WithdrawnPrimary
Tissue Collection to ID TCRs From Renal Clear Cell Carcinoma Patients Responding to Immune Checkpoint Inhibitors
Showing all 5 trials